Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy pricing in the UK private market shifted noticeably in 2026, and if you've been watching the numbers, you're right to question what's driving that. The short answer: unlike Mounjaro, which saw a significant list-price increase from Eli Lilly in September 2025, Novo Nordisk has not announced a comparable hike for Wegovy — meaning some providers have held or adjusted their prices in response to market pressure. Private treatment still requires a prescription following a clinical assessment, and what you pay depends heavily on which dose you're taking, which provider you use, and what that price actually covers. Typical private Wegovy prices in 2026 range roughly £149–£375 per month depending on dose and provider, though these figures are widely reported estimates and individual quotes will vary. For a prescription medicine, cost is only one part of the picture — the clinical oversight sitting behind it matters just as much.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You searched, found a monthly figure that looked manageable, and clicked through. Then the basket looked different. This is the most common frustration our prescribers hear from patients who've shopped around before coming to us, and it's worth unpacking why it happens.
Private Wegovy pricing is priced per pen, per month, and the starting dose pen costs less than the maintenance dose pen. A headline figure advertising the lowest available number is almost always the 0.25mg starter price, the dose you'll spend your first month on before titration begins. If you want to understand how the cost changes at a specific point in the titration schedule, the 1mg dose has its own pricing page that breaks down what that stage costs. By the time you reach a therapeutic maintenance dose (the level where meaningful weight loss typically occurs), the monthly cost is substantially higher. That gap is rarely spelled out clearly on the landing page you find first.
Beyond dose, look at what the monthly price includes. Some services charge separately for the initial consultation, for prescription fees on each repeat, or for delivery. Others bundle a small number of aftercare check-ins but charge for clinical reviews beyond that. None of this is hidden in bad faith, but it does mean that comparing two headline prices without knowing what each covers is comparing different things. If you want a full picture of what you're actually paying for, our Wegovy price page walks through every component so you can make a like-for-like comparison. The full cost of Wegovy in the UK is better understood as the sum of all those components, not just the pen itself.
According to NICE's appraisal of semaglutide (TA875), Wegovy is recommended for use within a specialist weight management service with appropriate multidisciplinary support, which gives you a sense of the clinical infrastructure a legitimate private service should be replicating.
The most significant UK pricing news in the GLP-1 market recently came from the Mounjaro side: Eli Lilly raised its UK list price substantially from September 2025, with the highest-dose pen rising from around £122 to roughly £330 in list terms (as widely reported in August 2025). Private provider prices for Mounjaro followed that upward.
Wegovy's position in 2026 is different. Novo Nordisk did not implement a comparable list-price increase, and private market prices for semaglutide have been more stable, and if you're curious whether any reductions have been passed on to patients, there's a dedicated page explaining what's happened with Wegovy pricing recently. That context matters if you're weighing up which treatment to ask about at consultation, though the clinical differences between the two medicines are equally relevant. The full Wegovy treatment overview covers the evidence on how semaglutide works and what results the STEP 1 trial reported.
One genuinely new development in 2026: the MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026 (the highest dose the medicine is licensed at) and trials at this dose reported average weight loss of around 20.7% over 72 weeks, approaching results seen with tirzepatide at its highest dose. Whether that dose becomes relevant to you, and when, is a clinical decision made with a prescriber, not a purchasing one. If you want to understand how individual pen costs break down across the range, the per-pen pricing page gives a clearer sense of how the cost curve changes as you titrate.
At nume, one price covers your consultation, your prescription, the treatment itself, and next-working-day delivery by DPD. When your order arrives (a plain, unmarked box at your door with a tracking notification on your phone) everything needed is inside. There are no add-on fees for aftercare messages, no charge for the clinical re-review that happens before every repeat order, and no subscription pulling money from your account automatically. Each repeat is a fresh clinical decision.
We don't position ourselves as the least expensive option. Cheapest isn't a race we entered. What the price reflects is a GPhC-registered pharmacy operating through the licensed UK supply chain, with every consultation personally read by a real prescriber the same day it's submitted. You can verify our pharmacy registration directly on the GPhC register (9012878).
For a prescription medicine, price is the wrong test on its own. The question that actually protects you is whether the service is verifiable, whether a qualified prescriber is making the clinical call, and whether the medicine is coming through an authorised supply chain. Our clinical and pharmacy team is built around those standards, and if you want to understand our prescribers' approach in more detail, our clinical lead's profile is there to read. To explore your options and check your eligibility, the weight-loss treatments overview is a good starting point.
Wegovy is a Prescription-Only Medicine. Under UK law, it can only be legally supplied following a clinical assessment by a qualified prescriber. The MHRA has issued repeated warnings about counterfeit weight-loss pens circulating online, some containing insulin rather than the labelled medicine, a risk that can be genuinely dangerous. Any seller offering these medicines without a prior prescription from a registered prescriber is operating illegally, whatever the price. You can report suspect sellers at the MHRA's Yellow Card service.
Discount codes for prescription medicines from unverified sources are one of the cleaner red flags. Legitimate services (ones with a registered pharmacy, real prescribers and an authorised supply chain) don't discount a POM to win business. We don't offer codes or vouchers. What we offer is a clinical service that happens to include everything in one price, with no surprises. If pricing is on your mind, the FAQs page answers the most common questions about what's included.
When you're ready to have a proper clinical conversation about whether Wegovy is right for you, check your eligibility and start a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.